Arlington, MA, United States of America

Duan Liu


 

Average Co-Inventor Count = 11.1

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2013-2016

Loading Chart...
Loading Chart...
7 patents (USPTO):

Title: Duan Liu: Innovator in Pharmaceutical Chemistry

Introduction

Duan Liu is a prominent inventor based in Arlington, MA (US), known for his significant contributions to pharmaceutical chemistry. With a total of seven patents to his name, Liu has made remarkable strides in the development of compounds that target critical pathways in various diseases.

Latest Patents

Among his latest innovations are the Pyrazolo[1,5-a]pyrimidine compounds, which serve as mTOR inhibitors. This invention provides a novel class of compounds that are useful in treating cancer and other disorders associated with deregulated mTOR pathways. Another notable patent is for Cycloalkylnitrile pyrazole carboxamides, which act as Janus kinase (JAK) inhibitors. These compounds are particularly beneficial for treating JAK-mediated diseases such as rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD), and cancer.

Career Highlights

Duan Liu is currently employed at Merck Sharp & Dohme Corporation, a leading global healthcare company. His work focuses on the discovery and development of innovative therapeutic solutions that address unmet medical needs.

Collaborations

Liu has collaborated with esteemed colleagues, including Lianyun Zhao and M Arshad Siddiqui, to advance his research and patent applications. Their combined expertise has contributed to the successful development of groundbreaking pharmaceutical compounds.

Conclusion

Duan Liu's contributions to the field of pharmaceutical chemistry are noteworthy, particularly in the development of compounds that target critical disease pathways. His innovative work continues to pave the way for new treatments in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…